Trilineage response to rhG-CSF with subsequent clonal hematopoiesis in a patient with severe bone marrow aplasia.
We treated a patient with severe aplastic anemia with long-term administration of recombinant human granulocyte-colony stimulating factor (rhG-CSF). When a trilineage response of hematopoiesis was obtained after the first treatment, a chromosomal change [45XX, -7] was observed in 20 of the 20 metaphases examined. Later, we were able to show a monoclonal X inactivation pattern in the phosphoglycerate kinase (PGK) gene in the peripheral blood polymorphonuclear leukocytes and mononuclear cells, indicating the presence of clonal hematopoiesis regardless of the disappearance of the karyotype abnormality. We suggest that it is important to pay close attention to the appearance of clonal hematopoiesis during the administration of G-CSF to patients with idiopathic severe bone marrow aplasia.
Yasuda
M
M
Department of Clinical Immunology, Kyushu University, Beppu Oita, Japan.
Shiokawa
S
S
Yamaguchi
M
M
Suenaga
Y
Y
Wada
T
T
Nonaka
S
S
Nobunaga
M
M
D000328:Adult; D000741:Anemia, Aplastic / Q000188:drug therapy* / Q000235:genetics; D001853:Bone Marrow / Q000187:drug effects / Q000502:physiology; D002869:Chromosome Aberrations; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects* / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D007621:Karyotyping; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000502:physiology; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor